Baseline characteristics
| NDND ET group (n=37) | DAWN group (n=45) | P value (DAWN vs NDND) | DEFUSE-3 group (n=47) | P value (NDND vs DEFUSE-3) | NDND non- ET group (n=105) | |
| Demographics | ||||||
| Age (median, IQR) | 77 (62–86) | 73.5 (61–83) | 0.46 | 75 (61–85) | 0.96 | 67 (59.5–82) |
| Male sex | 51% (19) | 47% (21) | 0.74 | 38% (18) | 0.35 | 46% (48) |
| Past medical history | ||||||
| Hypertension | 78% (29) | 60% (27) | 0.24 | 51% (24) | 0.01 | 69% (72) |
| Diabetes mellitus | 22% (8) | 16% (7) | 0.45 | 19% (9) | 0.77 | 26% (27) |
| Atrial fibrillation | 43% (16) | 27% (12) | 0.47 | 36% (17) | 0.50 | 41% (43) |
| Tobacco | 24% (9) | 9% (4) | 0.05 | 13% (6) | 0.16 | 22% (23) |
| Past stroke | 19% (7) | 11% (5) | 0.3 | 11% (5) | 0.28 | 11% (11) |
| CAD/CHF | 38% (14) | 18% (8) | 0.06 | 13% (6) | 0.007 | 14% (15) |
| Clinical characteristics | ||||||
| Admission NIHSS score | 18 (13–21) | 16 (13–20) | 0.45 | 16 (10–19) | 0.04 | 18 (13–22) |
| % Baseline mRS >2 | 24% (9) | 0% (0) | 0.0004 | 0% (0) | 0.0003 | 28% (29) |
| LKW to arrival (min) | 539 (432–766) | 707 (459–889) | 0.19 | 632 (427–800) | 0.74 | 730 (480–991.5) |
| % of witnessed strokes | 30% (11) | 11% | 0.03 | 11% | 0.02 | 21% (22) |
| % of transfer patients | 78% (29) | 71% (32) | 0.45 | 68% (32) | 0.29 | 78% (82) |
| Imaging characteristics | ||||||
| Infarct core volume (mL) | 7 (0–48) | 7 (3–16) | 0.72 | 7 (0–13) | 0.50 | 83 (33.25–161.75) |
| Site of occlusion§ | ||||||
| Intracranial ICA | 24% (9) | 16% (7) | 0.01 | 19% (9) | 0.01 | 10% (11) |
| MCA-M1 | 57% (21) | 84% (38) | 81% (38) | 67% (70) | ||
| MCA-M2 | 19% (7) | 0% (0) | 0% (0) | 23% (24) | ||
| Tandem lesions | 27% (10) | 5% (2) | 0.003 | 15% (7) | 0.16 | 17% (18) |
CAD, coronary artery disease; CHF, congestive heart failure; ICA, internal carotid artery; LKW, last known well; MCA, middle cerebral artery; M1 or M2, segment 1 or 2; NDND, non-DAWN non-DEFUSE-3 group.